Found: 124
Select item for more details and to access through your institution.
Economic and Humanistic Burden of Triple-Negative Breast Cancer: A Systematic Literature Review.
- Published in:
- 2022
- By:
- Publication type:
- journal article
Dose escalation and expansion cohorts in patients with advanced breast cancer in a Phase I study of the CDK7-inhibitor samuraciclib.
- Published in:
- Nature Communications, 2023, v. 14, n. 1, p. 1, doi. 10.1038/s41467-023-40061-y
- By:
- Publication type:
- Article
Author Correction: Dose escalation and expansion cohorts in patients with advanced breast cancer in a Phase I study of the CDK7-inhibitor samuraciclib.
- Published in:
- 2023
- By:
- Publication type:
- Correction Notice
heredERA Breast Cancer: a phase III, randomized, open-label study evaluating the efficacy and safety of giredestrant plus the fixed-dose combination of pertuzumab and trastuzumab for subcutaneous injection in patients with previously untreated HER2-positive, estrogen receptor-positive locally advanced or metastatic breast cancer
- Published in:
- BMC Cancer, 2024, v. 24, n. 1, p. 1, doi. 10.1186/s12885-024-12179-9
- By:
- Publication type:
- Article
Neoadjuvant immunotherapy and chemotherapy regimens for the treatment of high-risk, early-stage triple-negative breast cancer: a systematic review and network meta-analysis.
- Published in:
- BMC Cancer, 2023, v. 23, n. 1, p. 1, doi. 10.1186/s12885-023-11293-4
- By:
- Publication type:
- Article
Erratum to: 'Phase II/III weekly nab-paclitaxel plus gemcitabine or carboplatin versus gemcitabine/carboplatin as first-line treatment of patients with metastatic triple-negative breast cancer (the tnAcity study): study protocol for a randomized controlled trial.
- Published in:
- 2016
- By:
- Publication type:
- corrected article
Phase II/III weekly nab-paclitaxel plus gemcitabine or carboplatin versus gemcitabine/carboplatin as first-line treatment of patients with metastatic triple-negative breast cancer (the tnAcity study): study protocol for a randomized controlled trial.
- Published in:
- 2015
- By:
- Publication type:
- journal article
Gene Pathways Associated With Prognosis and Chemotherapy Sensitivity in Molecular Subtypes of Breast Cancer.
- Published in:
- JNCI: Journal of the National Cancer Institute, 2011, v. 103, n. 3, p. 264, doi. 10.1093/jnci/djq524
- By:
- Publication type:
- Article
Ductal lavage for detection of cellular atypia in women at high risk for breast cancer.
- Published in:
- 2001
- By:
- Publication type:
- journal article
Matching-adjusted indirect comparison of PFS and OS comparing ribociclib plus letrozole versus palbociclib plus letrozole as first-line treatment of HR+/HER2− advanced breast cancer.
- Published in:
- Therapeutic Advances in Medical Oncology, 2023, p. 1, doi. 10.1177/17588359231216095
- By:
- Publication type:
- Article
Quality of life with ribociclib versus abemaciclib as first-line treatment of HR+/HER2− advanced breast cancer: a matching-adjusted indirect comparison.
- Published in:
- Therapeutic Advances in Medical Oncology, 2023, p. 1, doi. 10.1177/17588359231152843
- By:
- Publication type:
- Article
AMEERA-5: a randomized, double-blind phase 3 study of amcenestrant plus palbociclib versus letrozole plus palbociclib for previously untreated ER+/HER2– advanced breast cancer.
- Published in:
- Therapeutic Advances in Medical Oncology, 2022, p. 1, doi. 10.1177/17588359221083956
- By:
- Publication type:
- Article
Patterns and Predictors of First-Line Taxane Use in Patients with Metastatic Triple-Negative Breast Cancer in US Clinical Practice.
- Published in:
- Current Oncology, 2021, v. 28, n. 4, p. 2741, doi. 10.3390/curroncol28040239
- By:
- Publication type:
- Article
Cost-Effectiveness of Neoadjuvant Pembrolizumab Plus Chemotherapy Followed by Adjuvant Single-Agent Pembrolizumab for High-Risk Early-Stage Triple-Negative Breast Cancer in the United States.
- Published in:
- Advances in Therapy, 2023, v. 40, n. 3, p. 1153, doi. 10.1007/s12325-022-02365-1
- By:
- Publication type:
- Article
Development of acquired resistance to lapatinib may sensitise HER2-positive breast cancer cells to apoptosis induction by obatoclax and TRAIL.
- Published in:
- 2018
- By:
- Publication type:
- journal article
Challenges in the treatment of hormone receptor-positive, HER2-negative metastatic breast cancer with brain metastases.
- Published in:
- Cancer & Metastasis Reviews, 2016, v. 35, n. 2, p. 323, doi. 10.1007/s10555-016-9619-z
- By:
- Publication type:
- Article
Clinical effectiveness and safety of olaparib in BRCA-mutated, HER2-negative metastatic breast cancer in a real-world setting: final analysis of LUCY.
- Published in:
- Breast Cancer Research & Treatment, 2024, v. 204, n. 2, p. 237, doi. 10.1007/s10549-023-07165-x
- By:
- Publication type:
- Article
Investigating potential immune mechanisms of trilaciclib administered prior to chemotherapy in patients with metastatic triple-negative breast cancer.
- Published in:
- Breast Cancer Research & Treatment, 2023, v. 201, n. 2, p. 307, doi. 10.1007/s10549-023-07009-8
- By:
- Publication type:
- Article
Analysis of patients without and with an initial triple-negative breast cancer diagnosis in the phase 3 randomized ASCENT study of sacituzumab govitecan in metastatic triple-negative breast cancer.
- Published in:
- Breast Cancer Research & Treatment, 2022, v. 195, n. 2, p. 127, doi. 10.1007/s10549-022-06602-7
- By:
- Publication type:
- Article
Ipatasertib plus paclitaxel for PIK3CA/AKT1/PTEN-altered hormone receptor-positive HER2-negative advanced breast cancer: primary results from cohort B of the IPATunity130 randomized phase 3 trial.
- Published in:
- Breast Cancer Research & Treatment, 2022, v. 191, n. 3, p. 565, doi. 10.1007/s10549-021-06450-x
- By:
- Publication type:
- Article
Baseline characteristics and first-line treatment patterns in patients with HER2-positive metastatic breast cancer in the SystHERs registry.
- Published in:
- Breast Cancer Research & Treatment, 2021, v. 188, n. 1, p. 179, doi. 10.1007/s10549-021-06103-z
- By:
- Publication type:
- Article
Recurrence rates in patients with HER2+ breast cancer who achieved a pathological complete response after neoadjuvant pertuzumab plus trastuzumab followed by adjuvant trastuzumab: a real-world evidence study.
- Published in:
- Breast Cancer Research & Treatment, 2021, v. 187, n. 3, p. 903, doi. 10.1007/s10549-021-06137-3
- By:
- Publication type:
- Article
Real-world survival outcomes of heavily pretreated patients with refractory HR+, HER2−metastatic breast cancer receiving single-agent chemotherapy—a comparison with MONARCH 1.
- Published in:
- Breast Cancer Research & Treatment, 2020, v. 184, n. 1, p. 161, doi. 10.1007/s10549-020-05838-5
- By:
- Publication type:
- Article
Phase Ib clinical trial of the anti-frizzled antibody vantictumab (OMP-18R5) plus paclitaxel in patients with locally advanced or metastatic HER2-negative breast cancer.
- Published in:
- Breast Cancer Research & Treatment, 2020, v. 184, n. 1, p. 53, doi. 10.1007/s10549-020-05817-w
- By:
- Publication type:
- Article
Treatment options for patients with HR+/HER2− advanced breast cancer during the COVID-19 pandemic: dose reduction of ribociclib does not diminish efficacy.
- Published in:
- 2020
- By:
- Publication type:
- Letter
A randomized, double-blind, phase 2 study of ruxolitinib or placebo in combination with capecitabine in patients with advanced HER2-negative breast cancer and elevated C-reactive protein, a marker of systemic inflammation.
- Published in:
- Breast Cancer Research & Treatment, 2018, v. 170, n. 3, p. 547, doi. 10.1007/s10549-018-4770-6
- By:
- Publication type:
- Article
Health-related quality of life of postmenopausal women with hormone receptor-positive, human epidermal growth factor receptor 2-negative advanced breast cancer treated with ribociclib + letrozole: results from MONALEESA-2.
- Published in:
- Breast Cancer Research & Treatment, 2018, v. 170, n. 3, p. 535, doi. 10.1007/s10549-018-4769-z
- By:
- Publication type:
- Article
Ribociclib plus letrozole versus letrozole alone in patients with de novo HR+, HER2− advanced breast cancer in the randomized MONALEESA-2 trial.
- Published in:
- Breast Cancer Research & Treatment, 2018, v. 168, n. 1, p. 127, doi. 10.1007/s10549-017-4518-8
- By:
- Publication type:
- Article
Erratum to: Prolonged survival in patients with breast cancer and a history of brain metastases: results of a preplanned subgroup analysis from the randomized phase III BEACON trial.
- Published in:
- 2017
- By:
- Publication type:
- Erratum
Prolonged survival in patients with breast cancer and a history of brain metastases: results of a preplanned subgroup analysis from the randomized phase III BEACON trial.
- Published in:
- Breast Cancer Research & Treatment, 2017, v. 165, n. 2, p. 329, doi. 10.1007/s10549-017-4304-7
- By:
- Publication type:
- Article
Paclitaxel, bevacizumab, and everolimus/placebo as first-line treatment for patients with metastatic HER2-negative breast cancer: a randomized placebo-controlled phase II trial of the Sarah Cannon Research Institute.
- Published in:
- Breast Cancer Research & Treatment, 2015, v. 154, n. 1, p. 89, doi. 10.1007/s10549-015-3599-5
- By:
- Publication type:
- Article
Development of a robust RNA-based classifier to accurately determine ER, PR, and HER2 status in breast cancer clinical samples.
- Published in:
- Breast Cancer Research & Treatment, 2014, v. 148, n. 2, p. 315, doi. 10.1007/s10549-014-3163-8
- By:
- Publication type:
- Article
Erratum to: Phase 2 study of eribulin mesylate as first-line therapy for locally recurrent or metastatic human epidermal growth factor receptor 2-negative breast cancer.
- Published in:
- 2014
- By:
- Publication type:
- Erratum
Phase 2 study of eribulin mesylate as first-line therapy for locally recurrent or metastatic human epidermal growth factor receptor 2-negative breast cancer.
- Published in:
- Breast Cancer Research & Treatment, 2014, v. 146, n. 2, p. 321, doi. 10.1007/s10549-014-2923-9
- By:
- Publication type:
- Article
Targeting HER2/HER3 co‐mutations in metastatic breast cancer: Case reports of exceptional responders to trastuzumab and pertuzumab therapy.
- Published in:
- Cancer Reports, 2024, v. 7, n. 3, p. 1, doi. 10.1002/cnr2.1954
- By:
- Publication type:
- Article
Evaluating health-related quality-of-life therapeutic effectiveness in a clinical trial with extensive nonignorable missing data and heterogeneous response: results from a phase III randomized trial of gemcitabine plus paclitaxel versus paclitaxel monotherapy in patients with metastatic breast cancer
- Published in:
- Quality of Life Research, 2012, v. 21, n. 5, p. 765, doi. 10.1007/s11136-011-9999-z
- By:
- Publication type:
- Article
Pilot clinical trial and phenotypic analysis in chemotherapy-pretreated, metastatic triple-negative breast cancer patients treated with oral TAK-228 and TAK-117 (PIKTOR) to increase DNA damage repair deficiency followed by cisplatin and nab paclitaxel.
- Published in:
- Biomarker Research, 2023, v. 11, n. 1, p. 1, doi. 10.1186/s40364-023-00511-7
- By:
- Publication type:
- Article
Matching-Adjusted Indirect Comparison of Ribociclib Plus Fulvestrant versus Palbociclib Plus Letrozole as First-Line Treatment of HR+/HER2− Advanced Breast Cancer.
- Published in:
- Cancer Management & Research, 2021, v. 13, p. 8179, doi. 10.2147/CMAR.S325043
- By:
- Publication type:
- Article
Chemoprevention of breast cancer.
- Published in:
- JAMA: Journal of the American Medical Association, 1996, v. 275, n. 17, p. 1349, doi. 10.1001/jama.1996.03530410063035
- By:
- Publication type:
- Article
Dose-intensive therapy for breast cancer.
- Published in:
- JAMA: Journal of the American Medical Association, 1993, v. 270, n. 17, p. 2089, doi. 10.1001/jama.1993.03510170079035
- By:
- Publication type:
- Article
Prevalence of germline BRCA mutations in HER2-negative metastatic breast cancer: global results from the real-world, observational BREAKOUT study.
- Published in:
- 2020
- By:
- Publication type:
- journal article
Correction to: Prevalence of mutations in BRCA and homologous recombination repair genes and real-world standard of care of Asian patients with HER2-negative metastatic breast cancer starting first-line systemic cytotoxic chemotherapy: subgroup analysis of the global BREAKOUT study
- Published in:
- 2022
- By:
- Publication type:
- Correction Notice
Prevalence of mutations in BRCA and homologous recombination repair genes and real-world standard of care of Asian patients with HER2-negative metastatic breast cancer starting first-line systemic cytotoxic chemotherapy: subgroup analysis of the global BREAKOUT study
- Published in:
- Breast Cancer (13406868), 2022, v. 29, n. 1, p. 92, doi. 10.1007/s12282-021-01283-4
- By:
- Publication type:
- Article
De Novo Versus Recurrent HER2‐Positive Metastatic Breast Cancer: Patient Characteristics, Treatment, and Survival from the SystHERs Registry.
- Published in:
- Oncologist, 2020, v. 25, n. 2, p. e214, doi. 10.1634/theoncologist.2019-0446
- By:
- Publication type:
- Article
Evaluation of Miracle Mouthwash plus Hydrocortisone Versus Prednisolone Mouth Rinses as Prophylaxis for Everolimus‐Associated Stomatitis: A Randomized Phase II Study.
- Published in:
- Oncologist, 2019, v. 24, n. 9, p. 1153, doi. 10.1634/theoncologist.2018-0340
- By:
- Publication type:
- Article
Eribulin Monotherapy in Patients Aged 70 Years and Older With Metastatic Breast Cancer.
- Published in:
- Oncologist, 2014, v. 19, n. 4, p. 318, doi. 10.1634/theoncologist.2013-0282
- By:
- Publication type:
- Article
Five‐year results of a phase II trial of preoperative 5‐fluorouracil, epirubicin, cyclophosphamide followed by docetaxel with capecitabine (wTX) (with trastuzumab in HER2‐positive patients) for patients with stage II or III breast cancer
- Published in:
- Cancer Medicine, 2018, v. 7, n. 6, p. 2288, doi. 10.1002/cam4.1472
- By:
- Publication type:
- Article
The hedgehog pathway in triple-negative breast cancer.
- Published in:
- Cancer Medicine, 2016, v. 5, n. 10, p. 2989, doi. 10.1002/cam4.833
- By:
- Publication type:
- Article
Oral mucosal injury caused by mammalian target of rapamycin inhibitors: emerging perspectives on pathobiology and impact on clinical practice.
- Published in:
- Cancer Medicine, 2016, v. 5, n. 8, p. 1897, doi. 10.1002/cam4.761
- By:
- Publication type:
- Article
Genomic alterations in DNA repair and chromatin remodeling genes in estrogen receptor-positive metastatic breast cancer patients with exceptional responses to capecitabine.
- Published in:
- Cancer Medicine, 2015, v. 4, n. 8, p. 1289, doi. 10.1002/cam4.464
- By:
- Publication type:
- Article